- Home
- REGN vs CM Comparison
REGN vs CM Comparison
Compare REGN & CM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- CM
- Stock Information
- Founded
- REGN 1988
- CM 1867
- Country
- REGN United States
- CM Canada
- Employees
- REGN N/A
- CM N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- CM
- Sector
- REGN Health Care
- CM
- Exchange
- REGN Nasdaq
- CM Nasdaq
- Market Cap
- REGN 56.7B
- CM 63.2B
- IPO Year
- REGN 1991
- CM N/A
- Fundamental
- Price
- REGN $567.74
- CM $73.16
- Analyst Decision
- REGN Buy
- CM Buy
- Analyst Count
- REGN 22
- CM 2
- Target Price
- REGN $840.95
- CM $109.00
- AVG Volume (30 Days)
- REGN 987.0K
- CM 1.6M
- Earning Date
- REGN 08-01-2025
- CM 08-28-2025
- Dividend Yield
- REGN 0.62%
- CM 3.74%
- EPS Growth
- REGN 16.49
- CM 21.34
- EPS
- REGN 39.43
- CM 5.76
- Revenue
- REGN $14,085,700,000.00
- CM $18,413,396,817.00
- Revenue This Year
- REGN N/A
- CM $22.48
- Revenue Next Year
- REGN $6.77
- CM $3.69
- P/E Ratio
- REGN $14.40
- CM $12.69
- Revenue Growth
- REGN 7.52
- CM 17.21
- 52 Week Low
- REGN $476.49
- CM $47.55
- 52 Week High
- REGN $1,211.20
- CM $73.52
- Technical
- Relative Strength Index (RSI)
- REGN 63.13
- CM 73.86
- Support Level
- REGN $532.60
- CM $71.10
- Resistance Level
- REGN $559.46
- CM $73.52
- Average True Range (ATR)
- REGN 14.29
- CM 0.86
- MACD
- REGN 6.52
- CM 0.13
- Stochastic Oscillator
- REGN 98.82
- CM 91.18
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About CM Canadian Imperial Bank of Commerce
Canadian Imperial Bank of Commerce is Canada's fifth-largest bank with around CAD 1 trillion in assets. It operates four business segments: Canadian retail and business banking, Canadian commercial banking and wealth management, US commercial banking and wealth management, and capital markets. It serves approximately 14 million personal banking and business customers, primarily in Canada and the US.